Skip to main content

Table 2 Tumor response in evaluable patients according to RECIST

From: A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer

 n = 22
Objective response
 Complete response, n (%)0 (0.0)
 Partial response, n (%)13 (59.1)
 Stable disease, n (%)6 (27.3)
 Progressive disease, n (%)3 (13.6)
 Not evaluable, n (%)0 (0.0)
Objective response rate (%)13 (59.1)
 90% CI, %41.8–74.4
Disease control rate (%)19 (86.4)
 95% CI, %66.7–95.3